Tudor Investment Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-105,523
| Closed | -$6.15M | – | 3636 |
|
|
2025
Q4 | $6.27M | Buy |
+105,523
| New | +$5.74M | 0.01% | 1014 |
|
|
2025
Q3 | – | Sell |
-57,750
| Closed | -$3.3M | – | 3377 |
|
|
2025
Q2 | $3.17M | Sell |
57,750
-17,316
| -23% | -$1.02M | 0.01% | 1356 |
|
|
2025
Q1 | $5.31M | Sell |
75,066
-24,659
| -25% | -$1.66M | 0.02% | 764 |
|
|
2024
Q4 | $6.55M | Buy |
99,725
+6,957
| +7% | +$466K | 0.02% | 556 |
|
|
2024
Q3 | $6.52M | Buy |
+92,768
| New | +$7.75M | 0.02% | 586 |
|
|
2023
Q1 | – | Sell |
-39,076
| Closed | -$4.04M | – | 2423 |
|
|
2022
Q4 | $4.04M | Buy |
+39,076
| New | +$3.67M | 0.08% | 314 |
|
|
2022
Q2 | – | Sell |
-7,976
| Closed | -$615K | – | 2111 |
|
|
2022
Q1 | $615K | Buy |
+7,976
| New | +$667K | 0.01% | 1155 |
|
|
2021
Q3 | – | Sell |
-2,814
| Closed | -$235K | – | 2464 |
|
|
2021
Q2 | $235K | Buy |
+2,814
| New | +$223K | ﹤0.01% | 1436 |
|
|
2021
Q1 | – | Sell |
-17,187
| Closed | -$1.51M | – | 1563 |
|
|
2020
Q4 | $1.51M | Buy |
17,187
+13,368
| +350% | +$1.06M | 0.04% | 539 |
|
|
2020
Q3 | $291K | Buy |
+3,819
| New | +$386K | 0.01% | 995 |
|
|
2020
Q1 | – | Sell |
-8,036
| Closed | -$679K | – | 1066 |
|
|
2019
Q4 | $679K | Sell |
8,036
-28,771
| -78% | -$2.17M | 0.03% | 629 |
|
|
2019
Q3 | $2.48M | Buy |
36,807
+5,754
| +19% | +$443K | 0.09% | 261 |
|
|
2019
Q2 | $2.66M | Buy |
31,053
+245
| +0.8% | +$21K | 0.08% | 239 |
|
|
2019
Q1 | $2.74M | Buy |
30,808
+5,290
| +21% | +$490K | 0.11% | 196 |
|
|
2018
Q4 | $2.17M | Sell |
25,518
-8,939
| -26% | -$850K | 0.04% | 175 |
|
|
2018
Q3 | $3.34M | Buy |
34,457
+16,795
| +95% | +$1.68M | 0.08% | 161 |
|
|
2018
Q2 | $1.66M | Buy |
+17,662
| New | +$1.55M | 0.06% | 294 |
|
|
2018
Q1 | – | Sell |
-10,373
| Closed | -$925K | – | 1010 |
|
|
2017
Q4 | $925K | Sell |
10,373
-9,392
| -48% | -$817K | 0.02% | 377 |
|
|
2017
Q3 | $1.84M | Buy |
19,765
+3,498
| +22% | +$309K | 0.05% | 233 |
|
|
2017
Q2 | $1.48M | Buy |
+16,267
| New | +$1.48M | 0.05% | 243 |
|
|
2015
Q4 | – | Sell |
-6,208
| Closed | -$654K | – | 1644 |
|
|
2015
Q3 | $654K | Buy |
6,208
+4,146
| +201% | +$554K | 0.02% | 609 |
|
|
2015
Q2 | $282K | Buy |
+2,062
| New | +$256K | 0.01% | 1133 |
|
|
2014
Q4 | – | Sell |
-5,913
| Closed | -$427K | – | 1454 |
|
|
2014
Q3 | $427K | Buy |
+5,913
| New | +$389K | 0.02% | 772 |
|
Other funds holding BMRN
VCM
VPM
Tudor Investment Corp's BMRN Position: Q1 2026 in Review
Tudor Investment Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 105,523 shares — an estimated $6.15M sold.
Tudor Investment Corp first reported a position in BMRN in Q3 2014 and held it in 23 quarters. The position peaked at $6.55M in Q4 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Tudor Investment Corp reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Tudor Investment Corp sold 105,523 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $6.15M.
- Tudor Investment Corp first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 23 quarters.
- Tudor Investment Corp's BioMarin Pharmaceuticals position peaked at $6.55M in Q4 2024.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.